Cargando…
Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease
Neuropathic Gaucher disease (nGD), also known as type 2 or type 3 Gaucher disease, is caused by a deficiency of the enzyme glucocerebrosidase (GC). This deficiency impairs the degradation of glucosylceramide (GluCer) and glucosylsphingosine (GluSph), leading to their accumulation in the brains of pa...
Autores principales: | Cabrera-Salazar, Mario A., DeRiso, Matthew, Bercury, Scott D., Li, Lingyun, Lydon, John T., Weber, William, Pande, Nilesh, Cromwell, Mandy A., Copeland, Diane, Leonard, John, Cheng, Seng H., Scheule, Ronald K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422338/ https://www.ncbi.nlm.nih.gov/pubmed/22912851 http://dx.doi.org/10.1371/journal.pone.0043310 |
Ejemplares similares
-
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease
por: Marshall, John, et al.
Publicado: (2016) -
Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease
por: Ashe, Karen M., et al.
Publicado: (2011) -
A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease
por: Fujii, Takahiro, et al.
Publicado: (2021) -
Ubiquitous Transgene Expression of the Glucosylceramide-Synthesizing Enzyme Accelerates Glucosylceramide Accumulation and Storage Cells in a Gaucher Disease Mouse Model
por: Barnes, Sonya, et al.
Publicado: (2014) -
Glucosylceramide synthase maintains influenza virus entry and infection
por: Drews, Kelly, et al.
Publicado: (2020)